Fig. 4
From: Myocyte enhancer factor 2D provides a cross-talk between chronic inflammation and lung cancer
Expressions of MEF2D in LPS-activated NSCLC cell line. a qRT-PCR analysis of MEF2D mRNA expression in total mRNA harvested from A549 cells challenged with PBS (LPS 0 μg/ml) or LPS at 0.01, 0.1, 1 μg/ml for 4 h; b qRT-PCR analysis of MEF2D mRNA expression in total mRNA harvested from A549 cells challenged with LPS at 1 μg/ml from 0 to 24 h; c Western blotting analysis of MEF2D protein expression in A549 cells challenged with PBS (LPS 0 μg/ml) or LPS at 0.01, 0.1, 1 μg/ml for 48 h; d Western blotting analysis of MEF2D protein expression in A549 cells challenged with LPS at 1 μg/ml from 0 to 72 h. Data were presented as mean ± S.E.M and each group had at least six measurements (**p < 0.01, ***p < 0.001, as compared with control group)